Respiri (ASX:RSH) - Executive Chairman, Nicholas Smedley
Executive Chairman, Nicholas Smedley
Source: Business Insider
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • eHealth software solutions company Respiri (RSH) has secured a product referral agreement with the Australian Patients Association (APA)
  • The APA is an independent charity that supports around 1.1 million Australian patients and protects their rights and interests
  • Under the agreement, the APA will provide patient referrals to Respiri once its wheezo device is launched in October
  • In exchange, Respiri will pay the APA a small commission on device sales
  • This deal follows the recently announced partnership between Respiri and the APA to support patients living with asthma through Respiri’s wheezo experiential program
  • Company shares are up 3.23 per cent and are trading for 16 cents

eHealth software solutions company Respiri (RSH) has secured a product referral agreement with the Australian Patients Association (APA).

The APA is an independent charity that supports Australian patients and protects their rights and interests. The APA is connected with 1.1 million Australian patients and 15,000 healthcare practitioners.

The agreement follows a recently announced partnership between Respiri and the APA to support patients living with asthma through Respiri’s wheezo experiential program.

The experiential program is a real-world asthma management study designed to support patients living with asthma. Asthma reportedly affects roughly 11 per cent of all Australians.

“We are delighted to have extended our productive relationship with the APA beyond our patient Experiential Program to a commercial agreement that seeks to educate and build awareness of the benefits of wheezo to APA’s extensive patient network within Australia,” Respiri CEO and Managing Director Marjan Mikel said.

Under the product referral agreement, the APA will utilise its customer network, database and referral codes to provide patient referrals to Respiri once wheezo is launched in October. In exchange, Respiri will pay the APA a small commission on device sales.

Company shares are up 3.23 per cent and are trading for 16 cents each at 12:45 pm AEST.

rsh by the numbers
More From The Market Online

Artrya expands US commercial momentum with five-year HonorHealth agreement

Atrya has signed a five-year commercial agreement with major Arizona health system HonorHealth and becomes fifth…

EVE Health Group signs Australian compounding agreement for rapidly rising Men’s Health issue

EVE Health Group has signed an agreement with Optimal Pharmacy Plus Stafford aimed at the Australian…

TruScreen Group advances Bangladesh opportunity to drive Indian subcontinent expansion

TruScreen Group has completed a successful product presentation and training visit to Dhaka, Bangladesh as part…

Argent Biopharma executes global licence for non-core Cannabis genetics

Argent BioPharma has entered into a worldwide licensing agreement with TPI for the commercial development of…